← Back to Clinical Trials
Recruiting NCT07254013

NCT07254013 Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of Portable ECG Solution

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07254013
Status Recruiting
Phase
Sponsor MicroPort CRM
Condition Bradycardia
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2025-11-14
Primary Completion 2026-02-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
LBBAP implant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 55 participants in total. It began in 2025-11-14 with a primary completion date of 2026-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the capability to monitor LBB success criteria with the use of a Smart ECG system (ECG monitor, 12 leads ECG cable, ECG viewer software ) during a cardiac device implantation involving the placement of a pacing lead in interventricular septum area

Eligibility Criteria

Inclusion Criteria: * Subject with indication for LBBAP using an Electrophysiology ECG monitoring system (EP System) as part of pacemaker or CRT-P or CRT-D implant procedure (de novo implant, device revision or upgrade including LOT-CRT) * Subject signed and dated the ICF Exclusion Criteria: * Incapacitated subject or under guardianship * inability to understand the purpose of the study * Minor subjects * Non menopausal women * Patients implanted with other electrically active non cardiac devices.

Contact & Investigator

Central Contact

Maria Martino, Project Manager

✉ maria.martino@crm.microport.com

📞 +393351005007

Principal Investigator

Dr Pierre- Antoine Catalan

PRINCIPAL INVESTIGATOR

University Hospital, Clermont-Ferrand

Frequently Asked Questions

Who can join the NCT07254013 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bradycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07254013 currently recruiting?

Yes, NCT07254013 is actively recruiting participants. Contact the research team at maria.martino@crm.microport.com for enrollment information.

Where is the NCT07254013 trial being conducted?

This trial is being conducted at Besançon, France, Clermont-Ferrand, France, Grenoble, France, Montpellier, France.

Who is sponsoring the NCT07254013 clinical trial?

NCT07254013 is sponsored by MicroPort CRM. The principal investigator is Dr Pierre- Antoine Catalan at University Hospital, Clermont-Ferrand. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology